Log In
BCIQ
Print this Print this
 

Yosprala, Yosprala 325/40 (PA32540)

  Manage Alerts
Collapse Summary General Information
Company Aralez Pharmaceuticals Inc.
DescriptionTablet containing 325 mg aspirin core surrounded by an immediate-release coating of 40 mg omeprazole, a proton pump inhibitor (PPI)
Molecular Target H+/K ATPase pump
Mechanism of ActionH+/K+ ATPase pump inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard Indication Cardiovascular (unspecified)
Indication DetailsSecondary prevention of cardio- and cerebrovascular events in patients at risk for developing aspirin-associated gastric ulcers; Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers; Secondary prevention of cardiovascular events
Regulatory Designation U.S. - Standard Review (Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$35.0M

$15.0M

$20.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/09/2013

$35.0M

$15.0M

$20.0M

Get a free BioCentury trial today